HCA Health Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? HCA Health Inc trades at $443.69 (market cap $95.08B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: HCA Health Inc is far larger — about 3.8× Roivant Sciences Ltd. Common Shares's market cap, and HCA Health Inc pays a 0.71% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| HCA | ROIV | |
|---|---|---|
Market Cap | $95.08B | $25.09B |
Volume | 998,787 | 5,738,571 |
Sector | Health | Health |
52-Week High | $545.13 | $41.81 |
52-Week Low | $361.32 | $16.04 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $145.62B | $21.36B |
Dividend Yield | 0.71% | — |
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.
The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →